Schotsaert, Michael

Animal models for COVID-19

Muñoz-Fontela, C., Dowling, W. E., Funnell, S. G. P., Gsell, P.-S., Riveros-Balta, A. X., Albrecht, R. A., Andersen, H., Baric, R. S., Carroll, M. W., Cavaleri, M., et al. (2020) · Nature

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 798

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

Jangra, S., Ye, C., Rathnasinghe, R., Stadlbauer, D., Alshammary, H., Amoako, A. A., Awawda, M. H., Beach, K. F., Bermúdez-González, M. C., Chernet, R. L., et al. (2021) · The Lancet Microbe

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 385

Virus-induced senescence is a driver and therapeutic target in COVID-19

Lee, S., Yu, Y., Trimpert, J., Benthani, F., Mairhofer, M., Richter-Pechanska, P., Wyler, E., Belenki, D., Kaltenbrunner, S., Pammer, M., et al. (2021) · Nature

Telomeres, Telomerase, and SenescenceCOVID-19 Clinical Research Studies

Cited by 350

Contribution of the Purinergic Receptor P2X7 to Development of Lung Immunopathology during Influenza Virus Infection

Leyva-Grado, V. H., Ermler, M. E., Schotsaert, M., Gonzalez, M. G., Gillespie, V., Lim, J. K., & García-Sastre, A. (2017) · mBio

Adenosine and Purinergic SignalingInfluenza Virus Research Studies

Cited by 47